Biomarkers: Technologies and Global Markets

  • ID: 3757816
  • Report
  • Region: Global
  • 171 Pages
  • BCC Research
15 % OFF
until Dec 31st 2018
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Banyan Biomarkers, Inc.
  • Boehringer Ingelheim Gmbh
  • Eisai Co., Ltd.
  • Genedata Ag
  • Merck & Co.
  • MORE
The Report Scope:

Current and projected biomarker market forecasts for the forecast period 2018 to 2023 are discussed. Products approved in the last three years by the U.S. Food and Drug Administration and products expected to be approved within the forecast period are projected. Due to the timing of this report, 2018 figures are estimated except where actual results have been reported.

This report includes an analysis of the leading and emerging competitors in the current worldwide biomarkers market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define specific product strategies that were employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles of the current market leaders, as well as companies with innovative products poised to advance within forecast period, are discussed.

In this report, market size and forecasts by segment, type, therapeutic area and geography from 2018 through 2023 have been provided. The study is arranged to offer an overview of the biomarkers market accompanied by product, company, geographic region or country. Virtually the entire globe is covered to include prevalent data for each disease subsegment. The report encompasses the use of major types of biomarkers for clinical and research applications. In addition, major applications that are being commercialized and developed by a wide range of companies, especially for drug discovery and development processes, are also considered. The application of biomarkers in the field of diagnostics and therapeutics for major indications such as cancer, immunological disorders, neurological disorders and others are also discussed.

Excluded from this report are over-the-counter (OTC) medications and other consumables that do not require a physician’s prescription.

Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

All market share data are presented on a global basis unless specifically noted.

The Report Includes:
  • 70 data tables and 42 additional tables
  • Industry analysis of the global biomarkers market
  • Country specific data and analysis for United States, Canada, Mexico, France, Germany, U.K., China, India, Japan, Middle East and Africa
  • Characterization and quantification of the market potential for biomarkers by segment, product type, therapeutic area and geographical region
  • Encompassing details of major types of biomarkers and their use in clinical and research applications
  • Examination of regional market dynamics with a focus on regulatory development, key technology updates and major drivers impacting the global market
  • Assessment of the leading biotechnology companies poised to introduce products during the forecast period, and their impact on the face of the competitive environment
  • Detailed profiles of the leading biomarkers' manufacturers, including Abbott Laboratories, Bayer Group, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline and Novartis AG
Membership Price:

Contact us for membership pricing.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Banyan Biomarkers, Inc.
  • Boehringer Ingelheim Gmbh
  • Eisai Co., Ltd.
  • Genedata Ag
  • Merck & Co.
  • MORE

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Intended Audience
  • Methodology and Information Sources
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports

Chapter 2 Summary and Highlights

  • Market Context for Biomarkers

Chapter 3 Overview

  • Introduction
  • Biomarkers: Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
  • Challenges

Chapter 4 Regulatory Dynamics, Intellectual Property and Ethical Considerations

  • Introduction
  • Biomarker Laboratory Regulatory Summary
  • Definition of An IVD Companion Diagnostic
  • Regulatory Processes for New Technologies
  • Ensuring Safety and Effectiveness of Health Technologies
  • Review in The Developing World
  • Assay Development and Validation in Drug Diagnostic Co-development
  • Selection of Patients and Controls
  • Role of the Food and Drug Administration
  • FDA Guidelines for Biomarker Applications
  • European Medicines Agency
  • Regulatory Impact on Drug Safety

Chapter 5 Market Breakdown by Segment

  • Introduction
  • Market Breakdown
  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Imaging Biomarkers
  • Bioinformatics Related Biomarkers

Chapter 6 Market Breakdown by Therapeutic Area

  • Introduction
  • Market Breakdown
  • Oncology
  • Cardiology Biomarkers
  • Neurology
  • Immunology Biomarkers

Chapter 7 Market Breakdown by Type

  • Introduction
  • Market Breakdown
  • Disease-related Biomarkers
  • Drug-related Biomarkers
  • Molecular Biomarkers
  • Surrogate Biomarkers

Chapter 8 Market Breakdown by Region

  • Introduction
  • Regional Analysis
  • Overview
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 9 Competitive Landscape and Key Developments

  • Major Players and Market Structure Analysis
  • Key Developments
  • Drug Pipeline Analysis by Leading Manufacturers
  • Abbott Laboratories
  • Astellas Pharma
  • AstraZeneca
  • Bayer Group
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • Eli Lilly and Company
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical

Chapter 10 Company Profiles

  • ABBOTT LABORATORIES
  • Business Overview
  • Financials
  • Products and Services
  • AFFYMETRIX, INC.
  • Business Overview
  • Products and Services
  • ASTELLAS PHARMA, INC.
  • Business Overview
  • Financials
  • Products and Services
  • ASTRAZENECA PLC
  • Business Overview
  • Financials
  • Products and Services
  • BANYAN BIOMARKERS, INC.
  • Business Overview
  • Products and Services
  • BAYER GROUP
  • Business Overview
  • Financials
  • Products and Services
  • BG MEDICINE
  • Business Overview
  • Products and Services
  • BIOSYSTEMS INTERNATIONAL
  • Business Overview
  • Products
  • BOEHRINGER INGELHEIM GMBH
  • Business Overview
  • Financials
  • Products and Services
  • BRISTOL-MYERS SQUIBB
  • Business Overview
  • Financials
  • Products and Services
  • CAPRION PROTEOMICS INC.
  • Business Overview
  • Product and Services
  • DAIICHI SANKYO CO., LTD.
  • Business Overview
  • Financials
  • Products and Services
  • EISAI CO., LTD.
  • Business Overview
  • Financials
  • Products and Services
  • ELI LILLY AND CO.
  • Business Overview
  • Financials
  • Products and Services
  • EPIGENOMICS AG
  • Business Overview
  • Financials
  • Products and Services
  • GENEDATA AG
  • Business Overview
  • Products and Services
  • GENENEWS LTD.
  • Business Overview
  • Products and Services
  • GLAXOSMITHKLINE
  • Business Overview
  • Financials
  • Products and Services
  • JOHNSON & JOHNSON
  • Business Overview
  • Financials
  • Products and Services
  • MERCK & CO.
  • Business Overview
  • Financials
  • Products and Services
  • NOVARTIS AG
  • Business Overview
  • Financials
  • PFIZER, INC.
  • Business Overview
  • Financials
  • Products and Services
  • QIAGEN N.V.
  • Business Overview
  • Financials
  • F. HOFFMANN-LA ROCHE LTD.
  • Business Overview
  • Financials
  • Products and Services
  • SANOFI-AVENTIS
  • Business Overview
  • Financials
  • Products and Services
  • TAKEDA PHARMACEUTICALS CO. LTD.
  • Business Overview
  • Financials
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • Business Overview
  • Financials

List of Tables
Summary Table A: Global Market for Biomarkers, by Segment, Through 2023
Summary Table B: Global Market for Biomarkers, by Type, Through 2023
Summary Table C: Global Market for Biomarkers, by Therapeutic Area, Through 2023
Summary Table D: Global Market for Biomarkers, by Region, Through 2023
Table 1: Notable NIH Grants for Biomarker Related Projects, 2018
Table 2: Global Market for Biomarkers, by Segment, Through 2023
Table 3: Global Market for Genomic Biomarkers, by Country/Region, Through 2023
Table 4: Global Market for Proteomics Biomarkers, by Country/Region, Through 2023
Table 5: Global Market for Imaging Biomarkers, by Country/Region, Through 2023
Table 6: Global Market for Bioinformatics Related Biomarkers, by Country/Region, Through 2023
Table 7: Global Market for Biomarkers, by Therapeutic Area, Through 2023
Table 8: Global Market for Biomarkers in Oncology, by Country/Region, Through 2023
Table 9: Global Market for Biomarkers in Cardiology, by Country/Region, Through 2023
Table 10: Global Market for Biomarkers in Neurology, by Country/Region, Through 2023
Table 11: Global Market for Biomarkers in Immunology, by Country/Region, Through 2023
Table 12: Global Market for Biomarkers, by Type, Through 2023
Table 13: Global Market for Biomarkers, by Region, Through 2023
Table 14: North American Market for Biomarkers, by Country, Through 2023
Table 15: North American Market for Biomarkers, by Segment, Through 2023
Table 16: North American Market for Biomarkers, by Therapeutic Area, Through 2023
Table 17: U.S. Market for Biomarkers, by Segment, Through 2023
Table 18: U.S. Market for Biomarkers, by Therapeutic Area, Through 2023
Table 19: Canadian Market for Biomarkers, by Segment, Through 2023
Table 20: Canadian Market for Biomarkers, by Therapeutic Area, Through 2023
Table 21: Mexican Market for Biomarkers, by Segment, Through 2023
Table 22: Mexican Market for Biomarkers, by Therapeutic Area, Through 2023
Table 23: European Market for Biomarkers, by Country, Through 2023
Table 24: European Market for Biomarkers, by Segment, Through 2023
Table 25: European Market for Biomarkers, by Therapeutic Area, Through 2023
Table 26: German Market for Biomarkers, by Segment, Through 2023
Table 27: German Market for Biomarkers, by Therapeutic Area, Through 2023
Table 28: French Market for Biomarkers, by Segment, Through 2023
Table 29: French Market for Biomarkers, by Therapeutic Area, Through 2023
Table 30: U.K. Market for Biomarkers, by Segment, Through 2023
Table 31: U.K. Market for Biomarkers, by Therapeutic Area, Through 2023
Table 32: Rest of the European Market for Biomarkers, by Segment, Through 2023
Table 33: Rest of the European Market for Biomarkers, by Therapeutic Area, Through 2023
Table 34: Asia-Pacific Market for Biomarkers, by Country, Through 2023
Table 35: Asia-Pacific Market for Biomarkers, by Segment, Through 2023
Table 36: Asia-Pacific Market for Biomarkers, by Therapeutic Area, Through 2023
Table 37: Japanese Market for Biomarkers, by Segment, Through 2023
Table 38: Japanese Market for Biomarkers, by Therapeutic Area, Through 2023
Table 39: Chinese Market for Biomarkers, by Segment, Through 2023
Table 40: Chinese Market for Biomarkers, by Therapeutic Area, Through 2023
Table 41: Indian Market for Biomarkers, by Segment, Through 2023
Table 42: Indian Market for Biomarkers, by Therapeutic Area, Through 2023
Table 43: Rest of Asia-Pacific Market for Biomarkers, by Segment, Through 2023
Table 44: Rest of Asia-Pacific Market for Biomarkers, by Therapeutic Area, Through 2023
Table 45: Rest of the World Market for Biomarkers by Region, Through 2023
Table 46: Rest of the World Market for Biomarkers, by Segment, Through 2023
Table 47: Rest of the World Market for Biomarkers, by Therapeutic Area, Through 2023
Table 48: Global Ranking of Manufacturers in Biomarkers, 2017
Table 49: Abbott Laboratories: Mergers, Acquisitions and Product Launches
Table 50: Astellas Pharma: Mergers, Acquisitions and Product Launches
Table 51: Astra Zeneca: Mergers, Acquisitions and Product Launches
Table 52: Banyan Biomarkers: Product Launches
Table 53: Bristol Myers Squibb: Mergers, Acquisitions and Product Launches
Table 54: Caprion Proteomics: Mergers, Acquisitions and Product Launches
Table 55: Eisai Co.: Mergers and Acquisitions
Table 56: GeneNews: Product Launches
Table 57: Merck & Co: Product Launches
Table 58: Qiagen: Partnerships
Table 59: Abbott Laboratories: Biomarkers and Pipeline
Table 60: Astellas Pharma: R&D Pipeline, As of April 2018
Table 61: AstraZeneca: Late-Stage Pipeline 2018 and 2019
Table 62: Bayer Group: R&D Pipeline, As of April 2018
Table 63: Daiichi Sankyo: Major R&D Pipeline
Table 64: Eli Lilly and Co.: Medicines in Development
Table 65: Novartis: Global Product Pipeline, As of April 2018
Table 66: Sanofi-Aventis: Representative Clinical Trials Involving Biomarkers
Table 67: Sanofi-Aventis: R&D Pipeline
Table 68: Takeda Pharmaceuticals: Key Products and Pipeline
Table 69: Teva Pharmaceutical: Specialty R&D Pipeline
Table 70: Abbott Laboratories: Financials, 2016-2017
Table 71: Abbott Laboratories: Products
Table 72: Affymetrix, Inc.: Representative Clinical Trials Involving Biomarkers
Table 73: Astellas Pharma: Financials, 2016-2017
Table 74: Astellas Pharma: Representative Clinical Trials Involving Biomarkers
Table 75: AstraZeneca: Financials, 2016-2017
Table 76: AstraZeneca: Representative Clinical Trials Involving Biomarkers
Table 77: Banyan Biomarkers, Inc.: Representative Clinical Trials Involving Biomarkers
Table 78: Bayer Group: Financials, 2016-2017
Table 79: Bayer Schering: Representative Clinical Trials Involving Biomarkers
Table 80: BioSystems: Representative Clinical Trials Involving Biomarkers
Table 81: Boehringer: Financials, 2016-2017
Table 82: Bristol-Myers Squibb: Financials, 2016-2017
Table 83: Bristol-Myers Squibb: Representative Clinical Trials Involving Biomarkers
Table 84: Daiichi Sankyo Co., Ltd.: Recent Financials, 2016-2017
Table 85: Daiichi Sankyo Co., Ltd.: Representative Clinical Trials Involving Biomarkers
Table 86: Eisai Co., Ltd.: Recent Financials, 2016-2017
Table 87: Eisai Co., Ltd.: Representative Clinical Trials Involving Biomarkers
Table 88: Eli Lilly and Co.: Recent Financials, 2016 and 2017
Table 89: Eli Lilly and Co.: Representative Clinical Trials Involving Biomarkers
Table 90: Epigenomics AG: Recent Financials, 2016-2017
Table 91: Epigenomics AG: Representative Clinical Trials Involving Biomarkers
Table 92: Genedata AG: Representative Clinical Trials Involving Biomarkers
Table 93: GlaxoSmithKline: Recent Financials, 2016-2017
Table 94: GlaxoSmithKline: Representative Clinical Trials Involving Biomarkers
Table 95: Johnson & Johnson: Recent Financials, 2016-2017
Table 96: Johnson & Johnson: Representative Clinical Trials Involving Biomarkers
Table 97: Merck & Co.: Recent Financials, 2016-2017
Table 98: Merck & Co.: Representative Clinical Trials Involving Biomarkers
Table 99: Novartis AG: Financials, 2016-2017
Table 100: Pfizer, Inc.: Recent Financials, 2016-2017
Table 101: Pfizer, Inc.: Representative Clinical Trials Involving Biomarkers
Table 102: Qiagen N.V.: Recent Financials, 2016-2017
Table 103: Roche: Recent Financials, 2016-2017
Table 104: Roche: Representative Clinical Trials Involving Biomarkers
Table 105: Sanofi: Recent Financials, 2016-2017
Table 106: Sanofi: Representative Clinical Trials Involving Biomarkers
Table 107: Takeda Pharmaceutical: Recent Financials, 2016-2017
Table 108: Teva Pharmaceutical: Recent Financials, 2016-2017

List of Figures
Summary Figure: Global Market Shares for Biomarkers, by Region, 2017 vs. 2023
Figure 1: Global Prevalence of Cancer, 2016
Figure 2: Number of Companies with Active Pipelines, 2001-2017
Figure 3: Global Market Share for Biomarkers, by Region, 2017
Figure 4: Global Market for Biomarkers, by Region, 2018 vs. 2023
Figure 5: Abbott Laboratories: Revenue Share and Financials, 2015-2017
Figure 6: Abbott Laboratories: Revenue Share, by Segment, 2017
Figure 7: Abbott Laboratories: Revenue Share, by Region, 2017
Figure 8: Astellas Pharma.: Revenue Share and Financials, 2015-2017
Figure 9: Astellas Pharma.: Revenue Share, by Type of Product and Service, 2017
Figure 10: Astellas Pharma.: Revenue Share, by Region, 2017
Figure 11: AstraZeneca: Revenue Share and Financials, 2015-2017
Figure 12: AstraZeneca: Revenue Share, by Segment, 2017
Figure 13: AstraZeneca: Revenue Share, by Region, 2017
Figure 14: Bayer Group: Revenue Share and Financials, 2015-2017
Figure 15: Bayer Group: Revenue Share, by Segment, 2017
Figure 16: Bayer Group: Revenue Share, by Region, 2017
Figure 17: Boehringer: Revenue Share and Financials, 2015-2017
Figure 18: Boehringer: Revenue Share, by Segment, 2017
Figure 19: Boehringer: Revenue Share, by Region, 2017
Figure 20: Bristol-Myers Squibb: Revenue Share and Financials, 2015-2017
Figure 21: Bristol-Myers Squibb: Revenue Share, by Region, 2017
Figure 22: Daiichi Sankyo Co., Ltd.: Revenue Share and Financials, 2015-2017
Figure 23: Daiichi Sankyo Co., Ltd.: Revenue Share, by segment, 2017
Figure 24: Daiichi Sankyo Co., Ltd.: Revenue Share, by Region, 2017
Figure 25: Eisai Co., Ltd.: Revenue Share and Financials, 2015-2017
Figure 26: Eisai Co., Ltd.: Revenue Share, by Segment, 2017
Figure 27: Eisai Co., Ltd.: Revenue Share, by Region, 2017
Figure 28: Eli Lilly and Co.: Revenue Share and Financials, 2015-2017
Figure 29: Eli Lilly and Co.: Revenue Share, by Therapeutic Area, 2017
Figure 30: Eli Lilly and Co.: Revenue Share, by Region, 2017
Figure 31: Epigenomics AG: Revenue Share and Financials, 2015-2017
Figure 32: Epigenomics AG: Revenue Share, by Region, 2017
Figure 33: GlaxoSmithKline: Revenue Share and Financials, 2015-2017
Figure 34: GlaxoSmithKline: Revenue Share, by Segment, 2017
Figure 35: GlaxoSmithKline: Revenue Share, by Region, 2017
Figure 36: Johnson & Johnson: Revenue Share and Financials, 2015-2017
Figure 37: Johnson & Johnson, Revenue Share, by Segment, 2017
Figure 38: Johnson & Johnson: Revenue Share, by Region, 2017
Figure 39: Merck & Co.: Revenue Share and Financials, 2015-2017
Figure 40: Merck & Co.: Revenue Share, by Segment, 2017
Figure 41: Merck & Co.: Revenue Share, by Region, 2017
Figure 42: Novartis AG: Revenue Share and Financials, 2015-2017
Figure 43: Novartis AG: Revenue Share, by Segment, 2017
Figure 44: Novartis AG: Revenue Share, by Region, 2017
Figure 45: Pfizer, Inc.: Revenue Share and Financials, 2015-2017
Figure 46: Pfizer, Inc.: Revenue Share, by Segment, 2017
Figure 47: Pfizer, Inc.: Revenue Share, by Region, 2017
Figure 48: Qiagen N.V.: Revenue Share, Financials, 2015-2017
Figure 49: Qiagen N.V.: Revenue Share, by Segment, 2017
Figure 50: Qiagen N.V.: Revenue Share, by Region, 2017
Figure 51: Roche: Revenue Share and Financials, 2015-2017
Figure 52: Roche: Revenue Share, by Segment, 2017
Figure 53: Roche: Revenue Share, by Region, 2017
Figure 54: Sanofi: Revenue Share and Financials, 2015-2017
Figure 55: Sanofi: Revenue Share, by Segment, 2017
Figure 56: Sanofi: Revenue Share, by Region, 2017
Figure 57: Takeda Pharmaceutical: Recent Financials, 2015-2017
Figure 58: Takeda Pharmaceutical: Revenue Share, by Region, 2017
Figure 59: Teva Pharmaceutical: Revenue Share and Financials, 2015-2017
Figure 60: Teva Pharmaceutical: Revenue Share, by Segment, 2017
Figure 61: Teva Pharmaceutical: Revenue Share, by Region, 2017

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Laboratories
  • Affymetrix, Inc.
  • Astellas Pharma, Inc.
  • Astrazeneca Plc
  • Banyan Biomarkers, Inc.
  • Bayer Group
  • BG Medicine
  • Biosystems International
  • Boehringer Ingelheim Gmbh
  • Bristol-Myers Squibb
  • Caprion Proteomics Inc.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly And Co.
  • Epigenomics Ag
  • F. Hoffmann-La Roche Ltd.
  • Genedata Ag
  • Genenews Ltd.
  • Glaxosmithkline
  • Johnson & Johnson
  • Merck & Co.
  • Novartis Ag
  • Pfizer, Inc.
  • Qiagen N.V.
  • Sanofi-Aventis
  • Takeda Pharmaceuticals Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll